Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension

It remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy. To compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy. This was a randomised, open-label,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2019-11, Vol.76 (5), p.586-595
Hauptverfasser: Hackman, Greetta, Taari, Kimmo, Tammela, Teuvo L., Matikainen, Mika, Kouri, Mauri, Joensuu, Timo, Luukkaala, Tiina, Salonen, Arto, Isotalo, Taina, Pétas, Anssi, Hendolin, Niilo, Boström, Peter J., Aaltomaa, Sirpa, Lehtoranta, Kari, Hellström, Pekka, Riikonen, Jarno, Korpela, Merja, Minn, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Pukkala, Eero, Hemminki, Akseli
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:It remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy. To compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy. This was a randomised, open-label, parallel-group trial. A total of 250 patients were enrolled between April 2004 and October 2012 in eight Finnish hospitals, with pT2 with positive margins or pT3a, pN0, M0 cancer without seminal vesicle invasion. A total of 126 patients received adjuvant radiotherapy at 66.6Gy. The primary endpoint was biochemical recurrence-free survival, which we analysed using the Kaplan-Meier method and Cox proportional hazard regression. Overall survival, cancer-specific survival, local recurrence, and adverse events were secondary endpoints. The median follow-up time for patients who were alive when the follow-up ended was 9.3yr in the adjuvant group and 8.6yr in the observation group. The 10-yr survival for biochemical recurrence was 82% in the adjuvant group and 61% in the observation group (hazard ratio [HR] 0.26 [95% confidence interval {CI} 0.14–0.48], p
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2019.07.001